Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
CA 2272098 C · Owner: Ares, Jeffrey Joseph · Inventors: Bogdan, Sophie Eva; Henry, Raymond Todd; Ares, Jeffrey Joseph
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention involves compounds having the structure (1) (see figure I), wherein a) R1 is hydrogen; or C1-C3 alkanyl or C2-C3 alkenyl or nil; where R1 is nil, bond (a) is a double bond; b) D is CR2 and R2 is selected from hydrogen; unsubstituted C1-C3 alkanyl; amino, hydroxy mercapto; C1-C3 alkylthio or C1-, C3, alkoxy; C1-C3 alkylamino or C1-C3 dialkylamino and halo; or when B is CR3; D may, be N; c) B is NR9, CR3=CR8, CR3=N CR3, S, O, SO or SO2; wherein R9 is , selected from hydrogen; and unsubstituted C1-C3 alkanyl C2-C3 alkenyl or C2-C3 , alkynyl; C3, cycloalkanyl C3 cycloalkenyl; and wherein R3 and R8 are each independently selected from hydrogen; unsubstituted C1-C3 alkanyl C2-C3 …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 21, 1997 and granted November 11, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 21, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 21, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.